Paper
DNA-launched live-attenuated vaccines for biodefense applications
Published Apr 25, 2016 · S. Weaver, P. Pushko, I. Lukashevich
Expert Review of Vaccines
30
Citations
0
Influential Citations
Abstract
ABSTRACT A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.
DNA-launched live-attenuated vaccines offer reduced genetic reversions, increased safety, and improved immunization for biodefense applications against positive-strand RNA viruses.
Full text analysis coming soon...